800 Milligrams of CBD and a Hard Truth About What Cannabis Can and Can't Treat

800 Milligrams of CBD and a Hard Truth About What Cannabis Can and Can't Treat

For the millions of people living with the relentless nerve pain that follows a spinal cord injury, the options have always been grim: opioids that dull more than the pain, anticonvulsants with punishing side effects, and a long list of treatments that simply don't work. This week, a rigorously designed clinical trial offered a measured but genuine reason for hope — and, in the same breath, the broader research record delivered a reminder that cannabis medicine still has more questions than answers.

The trial, published in eClinicalMedicine, tested high-dose cannabidiol against chronic neuropathic pain in patients with spinal cord injury. What makes it worth taking seriously is its design. Conducted at Neuroscience Research Australia, the study was randomized, double-blinded, and placebo-controlled with a crossover structure — the gold-standard architecture that guards against the placebo effect and wishful thinking that plague so much cannabis research. Forty adults with spinal cord injury and neuropathic pain lasting at least three months were enrolled, with 38 included in the primary analysis. Each participant received both oral CBD at doses up to 800 milligrams per day and a placebo across two separate six-week periods, divided by a four-week washout — meaning every patient served as their own control.

The results were positive but honest about their own size. Over six weeks, CBD reduced pain by approximately 14%, compared with 6.5% on placebo. That is a real, statistically meaningful difference, though not a miracle — a 14% reduction will not make chronic nerve pain disappear. The more intriguing signal lay beneath the average: some participants experienced more than 30% pain reduction, and the researchers noted an apparent subgroup effect, with CBD working substantially better in some individuals than others. Crucially, CBD was well tolerated even at high doses, with few serious side effects — an important finding given that the 800-milligram daily dose far exceeds what most consumers associate with over-the-counter CBD.

Why does this matter beyond the spinal-cord-injury community? Two reasons. First, it adds methodologically sound evidence to a field long criticized for relying on anecdote and low-quality studies. Second, the subgroup signal points toward the future of cannabinoid medicine: not a one-size-fits-all remedy, but a treatment that may work powerfully for a subset of patients we cannot yet identify in advance. The obvious next step is research aimed at finding the biomarkers or characteristics that distinguish responders from non-responders — the difference between a hopeful average and a targeted therapy.

The CBD pain trial did not arrive in a vacuum. It joins a steady stream of cannabinoid science: more than 70 cannabis-related studies have been published in 2026 alone, spanning pain, cancer, sleep, metabolism, inflammation, and wound healing. The oncology work has been especially active in the laboratory. Recent studies found that CBD reduced breast cancer cell viability and triggered cell death through pathways involving oxidative stress and mitochondrial dysfunction, and that an exosome-based oral CBD formulation slowed the growth of aggressive triple-negative breast cancer in mice while altering more than 1,000 cancer-related genes. These are genuinely promising results — but they demand a caveat that cannot be repeated often enough: cell-culture and mouse studies are early-stage science. The graveyard of medicine is full of compounds that shrank tumors in a petri dish and did nothing in humans. Encouraging is not the same as proven.

That distinction brings us to the week's necessary dose of humility. For all the enthusiasm around cannabis as medicine, two major 2026 reviews delivered a pointed corrective. After screening 5,774 studies, researchers found no good evidence that medicinal cannabis effectively treats anxiety, depression, or PTSD — three of the conditions for which patients most commonly seek it out. The finding doesn't prove cannabis can't help with mental health; it shows that the rigorous studies needed to demonstrate such benefits largely haven't been done, leaving a vast gap between how cannabis is used and what the science can actually support.

This is the real state of cannabis research in mid-2026: a field maturing unevenly. In some corners — neuropathic pain, certain forms of localized discomfort — well-built trials are beginning to deliver credible, if modest, evidence. In others, particularly mental health, the marketing has sprinted miles ahead of the data. The honest reader should hold both truths at once. The spinal-cord-injury trial is exactly the kind of careful, controlled work the field needs more of, and its findings genuinely matter for patients with few good options. The mental-health reviews are a reminder that legitimacy is earned study by study, not claimed by enthusiasm. As federal rescheduling eases the research restrictions that have hamstrung scientists for decades, the hope is that more of cannabis medicine will finally get the rigorous testing this week's best study models — turning a promising plant into a properly understood one.